Hyperinflammatory Syndromes in Intensive Care

Abstract

Hyperinflammatory syndromes represent a group of severe, life-threatening conditions characterized by excessive and dysregulated immune activation, often culminating in multiorgan dysfunction. In the intensive care setting, recognition and timely management are paramount, as these syndromes, including hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and cytokine release syndrome (CRS), can arise secondary to infections, malignancies, autoimmune diseases, or therapies such as CAR-T cell therapy. This review synthesizes current evidence, elucidates underlying mechanisms, and emphasizes guideline-driven clinical approaches to optimize patient outcomes.

Introduction

Hyperinflammatory syndromes have emerged as a critical challenge in intensive care units (ICUs) worldwide, particularly with the advent of novel immunotherapies and the global burden of severe viral infections. These syndromes are defined by an uncontrolled systemic inflammatory response, often resulting in rapid progression to shock, coagulopathy, and organ failure. Early identification is hindered by overlapping clinical features with sepsis and other systemic inflammatory conditions. This article provides an in-depth review of the epidemiology, pathophysiology, clinical presentation, diagnostic strategies, management protocols, and advances in the care of patients suffering from hyperinflammatory syndromes in the ICU, drawing upon recent PubMed-indexed literature and consensus guidelines.

Epidemiology / Disease Burden

The precise incidence of hyperinflammatory syndromes in critical care remains elusive due to diagnostic complexities and under-recognition. Recent studies estimate that secondary HLH occurs in up to 4% of adults admitted with severe infections or malignancies. During the COVID-19 pandemic, hyperinflammatory states such as multisystem inflammatory syndrome in adults (MIS-A) and CRS became increasingly reported, highlighting the syndromes significance. The high associated mortality, ranging from 40% to 68% depending on etiology and timeliness of intervention, underscores the significant disease burden in ICUs. Epidemiological patterns differ globally, with infectious triggers more common in low- and middle-income countries, whereas malignancy and iatrogenic causes predominate in high-resource settings.

Pathophysiology

Hyperinflammatory syndromes are driven by aberrant immune activation. In HLH and MAS, defective cytotoxic T-cell and natural killer (NK) cell function results in persistent antigen stimulation and unchecked macrophage activation. This leads to excessive release of pro-inflammatory cytokines such as IFN-γ, IL-1β, IL-6, IL-18, and TNF-α a phenomenon commonly termed a "cytokine storm." The downstream effects include endothelial dysfunction, capillary leak, disseminated intravascular coagulation (DIC), and multiorgan failure. In CAR-T cell-induced CRS, T-cell activation leads to macrophage recruitment and similar cytokine cascades. Genetic predispositions, infection, malignancy, and immune-modulating therapies can all tip the balance toward hyperinflammation. Understanding these mechanisms underpins both diagnostic and therapeutic advances.

Risk Factors

Recognized risk factors for hyperinflammatory syndromes include underlying hematologic malignancies, viral infections (notably EBV, CMV, SARS-CoV-2), autoimmune or autoinflammatory diseases, and recent exposure to biologic or immunomodulatory therapies. Genetic mutations in perforin or related cytolytic pathway genes predispose to primary HLH, while secondary forms are more common in adults. Iatrogenic triggers such as CAR-T cell therapy or immune checkpoint inhibitors have expanded the risk landscape, necessitating heightened clinical vigilance in these populations. Early recognition of these risk factors is critical for prompt diagnosis and intervention.

Clinical Features

Patients typically present with persistent high-grade fevers, cytopenias, hepatosplenomegaly, and evidence of multiorgan dysfunction. Laboratory hallmarks include elevated ferritin (often >10,000 ng/mL), hypertriglyceridemia, hypofibrinogenemia, transaminitis, and elevated soluble IL-2 receptor (sCD25). Infectious, neoplastic, or autoimmune triggers may be apparent or occult. Distinguishing hyperinflammatory syndromes from severe sepsis or septic shock can be challenging due to overlapping clinical and laboratory features, but extreme hyperferritinemia, rapid deterioration despite antibiotics, and refractory shock are suggestive. Neurological involvement, coagulopathy, and acute respiratory distress syndrome (ARDS) are common in fulminant cases.

Diagnosis

Diagnosis relies on clinical suspicion supported by consensus criteria such as the HLH-2004 diagnostic guidelines, which combine clinical, laboratory, and histopathologic parameters. Key components include fever, splenomegaly, cytopenias, hypertriglyceridemia, hypofibrinogenemia, hemophagocytosis in bone marrow or tissue biopsies, elevated ferritin, and increased soluble CD25. Ancillary tests such as flow cytometry, NK cell activity, and genetic testing may be indicated in select cases. Exclusion of mimics (e.g., severe sepsis, malignancy progression) is essential. Advanced biomarkers including IL-18, CXCL9, and soluble CD163 have shown promise in risk stratification and monitoring response to therapy.

Treatment & Management

Management is multifaceted and time-sensitive. Supportive care with aggressive organ support (hemodynamic stabilization, ventilatory support, renal replacement therapy) is foundational. Immunomodulation remains the mainstay, with corticosteroids (e.g., dexamethasone) and etoposide forming the backbone of HLH protocols. In infection-associated cases, early broad-spectrum antimicrobials are vital. For MAS, high-dose steroids and cyclosporine are recommended. In CRS, IL-6 blockade with tocilizumab or siltuximab is highly effective, particularly in CAR-T cell therapy patients. Adjuncts such as IVIG, anakinra (IL-1 blockade), and plasmapheresis may be considered in refractory cases. Identification and treatment of underlying triggers (e.g., infection, malignancy) are crucial for sustained remission.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in the understanding and management of hyperinflammatory syndromes. The advent of biologic therapies targeting specific cytokines (e.g., IL-1, IL-6, IFN-γ) has transformed treatment paradigms, offering targeted immunosuppression with favorable safety profiles. Ruxolitinib (a JAK1/2 inhibitor) and emapalumab (an anti-IFN-γ antibody) are under investigation and have demonstrated efficacy in refractory HLH. Early genetic and biomarker-based risk stratification facilitates precision medicine approaches. The COVID-19 pandemic accelerated the use of IL-6 blockade in severe hyperinflammatory states, with compelling outcomes in selected cohorts. Ongoing trials continue to expand the therapeutic arsenal, promising improved prognosis for these critically ill patients.

Guideline Recommendations

Guidelines from the Histiocyte Society, American Society of Hematology, and recent expert consensus recommend a stepwise approach: high clinical suspicion, prompt diagnostic workup, rapid initiation of immunosuppression, and multidisciplinary care involving hematology, infectious disease, and critical care specialists. Early transfer to centers with expertise in managing hyperinflammatory syndromes is advised for complex cases. Protocolized management pathways, including standardized diagnostic algorithms and escalation plans for immunomodulatory therapies, are endorsed to optimize outcomes.

Conclusion

Hyperinflammatory syndromes present a formidable challenge in intensive care, demanding astute clinical recognition, rapid diagnostics, and timely, evidence-based therapy. Advances in pathophysiological understanding and the emergence of targeted biologics have improved prognosis, yet mortality remains high without early intervention. Multidisciplinary, guideline-driven approaches, ongoing research, and the integration of novel therapies hold promise for further improving outcomes in this critically ill population.